EICHORCondition: Open-Angle Glaucoma · Sponsor: AbbVie
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States. All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Vold Vision /ID# 245285 | Fayetteville, Arkansas, United States | — |
| UCLA Doheny Eye Center /ID# 227587 | Pasadena, California, United States | — |
| Ventura Ophthalmology /ID# 227585 | Ventura, California, United States | — |
| East Coast Institute for Research /ID# 255508 | Jacksonville, Florida, United States | — |
| Center for Sight - Sarasota /ID# 227577 | Sarasota, Florida, United States | — |
| New Vision Eye Center /ID# 261053 | Vero Beach, Florida, United States | — |
| Georgia Eye Partners /ID# 245203 | Atlanta, Georgia, United States | — |
| Stiles Eyecare Excellence /ID# 227576 | Overland Park, Kansas, United States | — |
| The Johns Hopkins Wilmer Eye Institute - Bethesda /ID# 245355 | Bethesda, Maryland, United States | — |
| Vance Thompson Vision /ID# 261125 | Alexandria, Minnesota, United States | — |
| Washington University-School of Medicine /ID# 245452 | St Louis, Missouri, United States | — |
| NYU Langone Medical Center /ID# 227583 | New York, New York, United States | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05411198